Oral tofacitinib, a Janus kinase (JAK) inhibitor, is gaining attention in dermatology for treating various inflammatory skin disorders, including alopecia areata, psoriasis and atopic dermatitis. A recent panel discussion highlighted its efficacy and safety profile, noting that tofacitinib can offer rapid improvements in patients who have not responded well to traditional therapies.